Healthcare Social Media and Updates
Healthcare Social Media and Updates
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
The Most Important Blood Test Your Doctor Doesn't Order You can have normal blood sugar, normal A1C, and normal cholesterol… and still be metabolically sick. In this episode, Dr. Robert Lufkin explains why fasting insulin may be the single most important blood test for predicting diabetes, heart disease, dementia, and even cancer — often years before they show up on routine labs . And how to get it if your doctor doesn't order it. https://youtu.be/ylkO3ETjEIE
With Vivtex deal, Novo gains a chance at better oral obesity drugs https://t.co/DhIelbC9jI by @gwendolynawu $NVO #obesity
Stand Up! with Pete Dominick: 1538 Dr Peter Hotez on the state of Vaccination in America. My latest with @PeteDominick https://t.co/LsuvmglNBx
I’m proud to introduce 𝐓𝐡𝐞 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐅𝐮𝐭𝐮𝐫𝐢𝐬𝐭’𝐬 𝟏𝟎𝟎 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐧𝐝 𝐀𝐈 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟔! The digital health and AI fields are saturated with hype, and distinguishing the promising players from the noise is a challenge. The annual list is our...
President Trump negotiated lower prices for some drugs on TrumpRx, but discounts only apply to cash paying patients not using their insurance. Many drugs already had big discounts through manufacturers or coupons, and some have generic equivalents that are already...
President Trump has called for his deals with drug companies to be enacted into legislation. It's hard to know what that means since the deals are not public.
Th FDA is absolutely correct, and confirms what I’ve said all along. This $IBRX @DrPatrick “lymphopenia” push means nothing until or unless they come up with real data showing patient benefit. The “number” doesn’t matter.
I love that biotech has returned to the "data in the morning, raise in the afternoon" way of living its best life. $VIR $PVLA
When decisions depend on milliseconds, moving data closer to where work happens matters. Edge computing and edge AI are reshaping manufacturing, energy, healthcare, and smart infrastructure, where latency, autonomy, and reliability are critical. More: https://t.co/0MYapoejKN @TMobileBusiness Partner
Given 1mg/week of Zepound showed 0.7% reduction in A1c in trials, and so is actually an efficacious dose, this microdose would just be $30/month. (Would imply using for longer than recommended after opening).
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D [Feb 17, 2026] Riedhammer et al. @LeukemiaJnl https://t.co/EyGBz7sEQz #mmsm #PrecisionMedicine #caxtx
Continuing medical education doesn’t have to mean stepping away from patients. Colin Banas, MD, explains how real-time access to evidence-based guidelines can reinforce learning and support patient care. 🔗https://t.co/BOGg49TELs @DrFirst @ElsevierConnect #CMEs #HITSM https://t.co/cGEozKOfKU
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager https://t.co/336c9FJdjt by @Lilah_Alvarado $VIR + 27% $JANX $ALPMY
Novo to cut GLP-1 drug prices; Palvella soars on study data https://t.co/UAs4IETgPX $NVO $PVLA+ 32% $GOSS $VNDA $PFE #biotech
Every org struggles with RCM—but not every org fixes what’s leaking revenue. This look at denials, claim errors, and today’s patient-pay realities makes the case for tightening processes now. https://t.co/lWo3nK666k #RCMFix #HITsm #HITSM #TempDev
We have a new quiz on how health insurance works. But, it's really a statement about how utterly complex health insurance is in the U.S. https://www.kff.org/private-insurance/quiz-how-well-do-you-understand-your-health-insurance/
Failing to find a buyer, BioMarin is voluntarily withdrawing Roctavian from the market. A fitting end for what was once one of the highest-profile gene therapies in development — and a reminder of the gap between promising science and a viable...
This survey of leaders from #healthcare plans, health systems, and innovative solution providers reflects optimism about clinical innovation and emerging #AI use, balanced against concerns over costs, payment models, and politics: https://t.co/xFXpbqfhbY via @TTCapPartners https://t.co/tG3a2CGn90
SaaS may be in its bloodbath moment but as @Bob_Wachter says: When AI replaces doctors it means we are all out of jobs. Doctors, writers, lawyers, consultants, knowledge workers, etc. Healthcare is highest regulation, liability, risk. It’ll be one of the...
The Miracles You’re Living Through (And Don’t Even Notice) by @PeterDiamandis and @Steven_Kotler https://t.co/jB8O0q00KT https://t.co/21Snf2EBxG
Novo, searching for a spark, spotlights new data for three-pronged obesity drug https://t.co/pPo9Oc1wlF $NVO $LLY #obesity
FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies https://t.co/OZW6Q27zMa via @Inside_PM
Big tech companies like Amazon, Google/Alphabet, Apple, NVIDIA and Microsoft are taking their move into healthcare and medicine seriously. They are developing new, health-related features on their platforms. They are also teaming up with research institutions and developers to create new...
As more patients live years—sometimes decades—beyond a cancer diagnosis, we need smarter, sustainable care models focused on improving quality of life. At @Oracle, we're use AI and real-world evidence to advance smarter, more equitable cancer care: https://t.co/h28j1sIrN3
The latest AI biotech raise comes not from the Bay Area or Boston, but out of Budapest Turbine has closed a $25M Series B, planning to build AI models that can simulate more and more lab experiments: https://t.co/Q31DVENA9G
I just started testing a new continuous glucose monitor (CGM) device from Syai. I tried Abbott Freestyle Libre 2 and Sibionics before, but the need for the reader with Libre was a pain in the process, and the Sibionics app is...
Slate starts up with $130M and a headache drug from China https://t.co/6DEltQAI8s by @gwendolynawu #biotech #startups $HLUBF
The future of medicine might be something you swallow. When I first read about PillBot, I paused. A tiny ingestible robot camera that replaces traditional endoscopies? That is not incremental innovation. That is a shift. Instead of invasive tubes and hospital procedures,...
The world’s largest health-focused AI app is from China now, with over 100 million (!) users. Ant Group just released this number and more details of what their plans are with the app. "Among its new users, 52% came from third-tier cities...
So the key here is look at how quickly $HROW's Vevye is catching up with $BLCO's Miebo - this is happening despite the Miebo head start (which provides a waterfall effect from refills) and way more extensive detailing and DTC...
Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency,...
Even our junk food is getting worse. Our food system has been hijacked, but we can take it back. Read labels. Choose whole foods. Demand better. h/t @drmarkhyman
I love my new AI personal trainer. In addition to knowing all my metabolic parameters & strength of each of my muscle groups, she also identifies imbalances and helps me correct it. Is this the future of strength training? https://egym.com/us
AI adoption in healthcare coding starts with people. Nick Judd of Cleveland Clinic shares why engaging caregivers from day one helped teams see generative AI as a support tool—not a replacement. 🔗https://t.co/cMNcrP9ZWl @ClevelandClinic @DukeHealth #AKASA #AHIMA25 #HITSM https://t.co/FtfPW5BWKP
NEW: The entire process of finding Medicare coverage may be influenced by artificial intelligence in the not-too-distant future. CMS wants to use AI tools for its "Medicare Experience Modernization" project — and there are lots of question marks. https://t.co/uSLFlAxViJ https://t.co/2bP3HnEDBx
Building off the Baby KJ success story: FDA unveils long-awaited guidance on new pathway for individualized therapies - https://t.co/Uetp1cGFq2
Generate estimated it would price its shares at $15 to $17 apiece, translating to a valuation ranging from $1.91 billion to $2.17 billion — not counting an underwriter's option: https://t.co/n9nJsbJuvm
Fostering relationships with disabled communities could invite meaningful feedback during the design of assistive technologies, which could spark innovations that serve diverse populations. Learn more in Science #Robotics: https://t.co/NmJ6c2KIS5 https://t.co/zlhagQkRbw
Why is $BCAX testing a ficera dose in phase 3 that it now says isn't optimal (and other uncomfortable questions)? Via @ApexOnco -> https://t.co/mLWKP6AAZ9 $JNJ $GMAB
As someone researching aging during a time when everyone is trying to extend lifespan (and not necessarily healthspan), I beg you to read this entire🧵. Unless something changes, this is your future reality. You may already be dealing with this if...
That feeling you get when you run a head-to-head study and the rival drug beats you out. Spending a fortune to hand your competitor a marketing message. Sometimes it feels like $NOVO is snake bit. $LLY https://t.co/gGUjl6iqPg
Goal-Driven Flexible Bayesian Design presentation updated w/comparison of performance of frequentist group sequential designs: https://t.co/QCZ6DQrm07 . Frequentist approach takes far too long to make a decision by controlling something that is NOT an error prob. #Statistics #rct https://t.co/X2knbmzTuX
My @CNBC segment on how President Trump's drug pricing deals will achieve many of the initial aims set out by tariff proposals, with respect to reshoring drug manufacturing, and how the biggest consumer impact in terms of lower drug costs...
Evaluating a doctor-in-the-loop AI-agent for multiple myeloma chart reviews [Nov 3, 2025] Karla Mariana Castro Bórquez et al. @HealthTree #ASH25 abs25-15262 PID 4424 https://t.co/MvBeHqOxCg #mmsm #AI #EMR #RWD https://t.co/onY817NfVr
Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants [Nov 3, 2025] Rajanna et al. @DrOlaLandgren #ASH25 abs25-11635 PID 4008 https://t.co/gOprMCjfgh #mmsm #AI #oncopath https://t.co/pjikEsgfHC
Race agnostic models maintain accuracy in predicting M-protein levels in multiple myeloma [Nov 3, 2025] @rahul2u et al. #ASH25 abs25-11347 PID 2810 https://t.co/A27ozBoW8h #mmsm #AI #CancerDisparities https://t.co/ubJ6NGMFUE
Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States [Nov 3, 2025] @MalekEhsanMD et al. #ASH25 abs25-11278 PID 2809 https://t.co/mAC8l7xnaG #mmsm #cancerdisparities #hpeonc https://t.co/veJxBV5S0N
Patient perspectives & preferences for step-up dosing and treatment w/ teclistamab & talquetamab: Insights from a patient survey [Nov 3, 2025] @JayHydren et al. @RahulBanerjeeMD abs25-8335 PID 6354 https://t.co/pRlflaSb2I #mmsm #Tcellrx @HealthTree https://t.co/3I9nwsxZMx
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 https://t.co/X2pdaIDYth #mmsm
Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey [Dec 7, 2024] @ManniMD1 et al. - @HealthTree https://t.co/jATJRKEfB2 #ASH24 Abst 2281 #mmsm HT @Taxkourel
